“While patients treated on regimens A and B were ….9% at 5 years, respectively), patients treated on regimen C were at a 16-fold increased risk … on regimen A. Increasing exposure to ifosfamide from 90 to 140 g/m2, cyclophosphamide from … increased the risk of t-MDS/AML significantly.”